E
86.19
0.41 (0.48%)
| Penutupan Terdahulu | 85.78 |
| Buka | 86.31 |
| Jumlah Dagangan | 2,613,704 |
| Purata Dagangan (3B) | 4,525,478 |
| Modal Pasaran | 50,602,151,936 |
| Harga / Pendapatan (P/E TTM) | 37.80 |
| Harga / Pendapatan (P/E Ke hadapan) | 29.85 |
| Harga / Jualan (P/S) | 8.39 |
| Harga / Buku (P/B) | 4.78 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Keuntungan | 75.71% |
| Margin Operasi (TTM) | 29.01% |
| EPS Cair (TTM) | 2.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 1.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.86% |
| Nisbah Semasa (MRQ) | 4.45 |
| Aliran Tunai Operasi (OCF TTM) | 876.20 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.45 B |
| Pulangan Atas Aset (ROA TTM) | 8.42% |
| Pulangan Atas Ekuiti (ROE TTM) | 16.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Edwards Lifesciences Corporatio | Menaik | Menaik |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.00 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.91% |
| % Dimiliki oleh Institusi | 89.29% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 104.00 (Goldman Sachs, 20.66%) | Beli |
| Median | 96.00 (11.38%) | |
| Rendah | 88.00 (Baird, 2.10%) | Pegang |
| Purata | 95.88 (11.24%) | |
| Jumlah | 11 Beli, 5 Pegang | |
| Harga Purata @ Panggilan | 84.34 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 05 Dec 2025 | 103.00 (19.50%) | Beli | 86.19 |
| 25 Nov 2025 | 100.00 (16.02%) | Beli | 86.82 | |
| Baird | 05 Dec 2025 | 88.00 (2.10%) | Pegang | 86.19 |
| Canaccord Genuity | 05 Dec 2025 | 89.00 (3.26%) | Pegang | 86.19 |
| 03 Nov 2025 | 84.00 (-2.54%) | Pegang | 83.07 | |
| RBC Capital | 05 Dec 2025 | 100.00 (16.02%) | Beli | 86.19 |
| 31 Oct 2025 | 95.00 (10.22%) | Beli | 82.45 | |
| Stifel | 05 Dec 2025 | 100.00 (16.02%) | Beli | 86.19 |
| 31 Oct 2025 | 95.00 (10.22%) | Beli | 82.45 | |
| Truist Securities | 05 Dec 2025 | 92.00 (6.74%) | Pegang | 86.19 |
| 03 Nov 2025 | 90.00 (4.42%) | Pegang | 83.07 | |
| UBS | 05 Dec 2025 | 92.00 (6.74%) | Pegang | 86.19 |
| Wells Fargo | 05 Dec 2025 | 96.00 (11.38%) | Beli | 86.19 |
| Barclays | 31 Oct 2025 | 99.00 (14.86%) | Beli | 82.45 |
| Citigroup | 31 Oct 2025 | 96.00 (11.38%) | Beli | 82.45 |
| Evercore ISI Group | 31 Oct 2025 | 92.00 (6.74%) | Beli | 82.45 |
| 07 Oct 2025 | 88.00 (2.10%) | Beli | 76.72 | |
| Goldman Sachs | 31 Oct 2025 | 104.00 (20.66%) | Beli | 82.45 |
| JP Morgan | 31 Oct 2025 | 90.00 (4.42%) | Pegang | 82.45 |
| Mizuho | 31 Oct 2025 | 100.00 (16.02%) | Beli | 82.45 |
| Piper Sandler | 31 Oct 2025 | 95.00 (10.22%) | Beli | 82.45 |
| Jefferies | 29 Oct 2025 | 98.00 (13.70%) | Beli | 82.69 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Dec 2025 | Pengumuman | Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference |
| 09 Nov 2025 | Pengumuman | Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease |
| 09 Nov 2025 | Pengumuman | Driving Timely Diagnosis And Treatment For Heart Valve Disease To Save Lives |
| 30 Oct 2025 | Pengumuman | Edwards Lifesciences Announces CFO Transition Plan |
| 30 Oct 2025 | Pengumuman | Edwards Lifesciences Reports Third Quarter Results |
| 27 Oct 2025 | Pengumuman | Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025 |
| 27 Oct 2025 | Pengumuman | Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 |
| 23 Oct 2025 | Pengumuman | Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |